• Molecular NameEscitalopram
  • SynonymCipralex; escitalopram; Escitalopram Oxalate
  • Weight323.411
  • Drugbank_IDDB01175
  • ACS_NO128196-01-0
  • Show 2D model
  • LogP (experiment)4.222
  • LogP (predicted, AB/LogP v2.0)3.99
  • pkaN/A
  • LogD (pH=7, predicted)1.67
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.91
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds6
  • TPSA12.47
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment in adults with major depressive disorder, generalized anxiety disorder, social anxiety disorder, or panic disorder.
  • Absorption_valueN/A
  • Absorption (description)The absolute bioavailability of citalopram is about 80% relative to an intravenous dose
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding56.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmLiver, specifically the enzymes CYP3A4 and CYP2C19
  • Half life27~32 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySigns of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A